Related Experiment Video
Updated: Jun 4, 2025
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
CD19-targeting chimeric antigen receptor T-cell therapy is safe and effective for intra-cardiac B cell non-Hodgkin
Daniel H Chen1,2,3, Maeve O'Reilly1,4, Kathleen P Cheok1,4
1University College Hospital University College London Hospitals NHS Foundation Trust London UK.
Introduction:
Chimeric antigen receptor T-cell (CAR-T) therapy is highly effective in B-cell blood cancers, but there is limited data on its safety and efficacy in intra-cardiac lymphoma, due to the potential risks of cardiotoxicity and pseudo-progression.
Discussion:
We discuss four high-risk cases that were managed with a multi-disciplinary approach, including baseline cardiac risk assessment and surveillance with multimodal cardiac imaging and serum cardiac biomarkers, elective supportive care in the intensive care unit, and early treatment of cytokine release syndrome.
Conclusion:
CAR-T therapy can be effective and safe in the treatment of B-cell blood cancers with intra-cardiac disease.
